Loading...
Market
Story
U.S. FDA Approves Perioperative Opdivo for Resectable NSCLC
Oct 3, 2024, 07:24 PM
The U.S. Food and Drug Administration (FDA) has approved the perioperative treatment of neoadjuvant Opdivo® (nivolumab) and chemotherapy followed by surgery and adjuvant single-agent Opdivo for resectable non-small cell lung cancer (NSCLC). Bristol-Myers Squibb (BMY) announced that the recommended dosage for nivolumab is 360 mg every three weeks for neoadjuvant treatment and 480 mg every four weeks for adjuvant treatment. This approval is expected to provide a new standard of care for patients with resectable NSCLC, enhancing treatment outcomes and potentially improving survival rates. These advancements reflect significant progress in the treatment of lung cancer, offering new hope for patients and healthcare providers.
View original story
Similar markets
Nausea • 25%
Fatigue • 25%
Diarrhea • 25%
Other • 25%
Cytokine release syndrome (CRS) • 25%
Immune effector cell-associated neurotoxicity syndrome (ICANS) • 25%
Secondary cancers • 25%
Other • 25%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Tecentriq Hybreza gains the most market share • 25%
Keytruda gains the most market share • 25%
Opdivo gains the most market share • 25%
Other treatment gains the most market share • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No significant side effects • 25%
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
No major side effects • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%